Non-Coding RNAs in Rheumatoid Arthritis: Implications for Biomarker Discovery

Julio Enrique Castañeda-Delgado 1,2,*, Noé Macias-Segura 3 and Cesar Ramos-Remus 4,*

Abstract: Recent advances in gene expression analysis techniques and increased access to technologies such as microarrays, qPCR arrays, and next-generation sequencing, in the last decade, have led to increased awareness of the complexity of the inflammatory responses that lead to pathology. This finding is also the case for rheumatic diseases, importantly and specifically, rheumatoid arthritis (RA). The coincidence in major genetic and epigenetic regulatory events leading to RA's inflammatory state is now well-recognized. Research groups have characterized the gene expression profile of early RA patients and identified a group of miRNAs that is particularly abundant in the early stages of the disease and miRNAs associated with treatment responses. In this perspective, we summarize the current state of RNA-based biomarker discovery and the context of technology adoption/implementation due to the COVID-19 pandemic. These advances have great potential for clinical application and could provide preclinical disease detection, follow-up, treatment targets, and biomarkers for treatment response monitoring.

Keywords: LncRNA; miRNA; biomarker; rheumatic disease

1. Novel Gene Expression Analysis Technologies for Biomarkers Discovery

Technologies that analyze gene expression, from qPCR machines to single-cell sequencing for single-cell transcriptomics, have been restricted mostly to research facilities [1]. The translation of these tools to clinical settings has been slow, perhaps due to the few tests being developed that have clinical value (e.g., detecting RNA or DNA from viruses such as HIV and HCV).

Recently, these tools have become available in many centers worldwide due to the COVID-19 pandemic, which required these centers to provide dynamic protocols for RNA detection and/or sequencing [2]. These resources could be used to further significant progress in areas such as inflammatory rheumatic diseases [3]. In the few pages ahead, we highlight the possible application of these technologies in the rheumatology setting using potential RNA-based biomarkers with special emphasis on RA.

2. Gene Expression Profiling of Rheumatic Diseases: Focus on RA

Rheumatoid arthritis is a complex disease involving several metabolic pathways, gene polymorphisms, and epigenetic alterations [4]. In this regard, identifying its gene expression profiles is a meaningful strategy to better understand the mechanisms of pathogenicity, disease course and progression, assess therapeutic response, and even treatment selection. Transcriptional profiling is a powerful technology capable of providing an integrative view of pathophysiological pathways. It evaluates thousands of molecules in one experiment [5]. Microarrays (MA) based on high-throughput platforms are among the most important...
tools for discovering new genetic, transcriptomic, or epigenetic disease alterations and identifying key future biomarkers for diagnosis, prognosis and response to therapy [6,7]. Microarray technology has been applied to compare RA patients’ gene expression profiles in a specific disease stage to healthy controls, other diseases, or another disease status of the same disease [8]. Molecular patterns identified by microarrays can be so specific that they differentiate particularities among patients with the same disease.

Transcriptomic assays supply vast information, which must be simplified to provide some context in systems biology. Many studies in the field use multiple strategies to simplify the metadata. One strategy to simplify gene expression data involves assessing changes in molecular patterns in a specific cell population. For example, dendritic cells (DCs) are important immune cells associated with the genesis of some autoimmune diseases. There is a specific transcriptional signature in DCs identified in three different autoimmune diseases, namely RA, systemic lupus erythematosus, and type 1 diabetes [9,10]. This transcriptomic profile in DCs is associated with two essential characteristics, the heterogeneity of the autoimmune disease and the disease activity level. These immune gene expression profiles provide essential clues to molecular pathways that can serve as determinants for therapy prognosis and disease course. These gene expression profiles can help to identify new molecular targets and treatment development.

We previously reported a specific transcriptional signature in peripheral blood cells associated with first-degree relatives negative to anti-cyclic citrullinated peptide antibodies (ACPA) that differentiate relatives positive to ACPA, and a specific transcriptional signature for treatment-naïve newly diagnosed RA patients [4]. Identifying these gene expression profiles brings new molecular pathways associated with disease course and diagnostic/prognostic candidate biomarkers for RA. One example is identifying the peripheral blood cell biomarkers SUMO1 (Small ubiquitin-like modifier 1) and POU2AF1 (POU domain class 2-associating Factor 1), which have decreased expression in patients with RA compared to first-degree relatives and negatively correlate with disease progression and ACPA levels [11]. Relatives with mild to low levels of these biomarkers can help identify patients with recent-onset RA in the “window of opportunity”, when treatment could have a beneficial effect on disease progression, even leading more effectively to clinical remission of RA [12].

Several studies have already focused on transcriptomics in RA, and have indeed provided plentiful data, some reporting important cell signatures associated with treatment response [6], the participation of T cells in early RA, ACPA [13], molecular differences between first-degree relatives with or without ACPA [4], and many others with substantial information in RA (Table 1). However, it is not currently practical to evaluate the gene expression profile for every patient with RA for diagnosis or to determine treatment failure or success. However, molecular markers obtained by different transcriptomic studies can help identify successful diagnostic biomarkers in clinical settings.

| Reference | Technology | Group(s) | Tissue Sample | Key Findings | Clinical Use |
|-----------|------------|----------|---------------|--------------|--------------|
| [14]      | Microarray | RA vs OA | Synovium      | Candidate biomarkers used together: IL7R + STAT1 (93.94% Sens; 80.77% Spec) | Diagnostic  |
| [15]      | Microarray | RA (early and established) vs OA | Synovium | Three candidate biomarkers accordingly to their AUC: GZMA (0.906), PRC1 (0.809) and TTK (0.793) | Diagnostic  |
| [16]      | Microarray | RA vs HC | Synovium      | Gene modules characterized by the gene expression of CCL5, CCL6, CCL9, CCL10, CCL13, and ADCY2 are potential BM for RA diagnosis | Diagnostic  |
**Table 1. Cont.**

| Reference | Technology | Group(s) | Tissue Sample | Key Findings | Clinical Use |
|-----------|------------|----------|---------------|--------------|--------------|
| [4]       | Microarray | RA vs FDR | Whole blood   | Gene expression profiles associated with RA in high risk relatives, and gene expression of BCL2, SERPINB9, MS4A1, ETS1, EGR1, CX3CL1 and MEF2A are potential BM for RA diagnostic | Diagnostic |
| [6]       | Microarray | RA responders to MTX vs RA nonresponders to MTX | Whole blood | Theoretical model was able to detect ~50% of nonresponders at the expense of a false negative rate of ~20% | Treatment response |
| [17]      | Firefly miRNA detection | Response to tofacitinib treatment | plasma | miRNA signature detection in plasma samples associated with clinical remission or RA flare | Treatment response |
| [7]       | miRNA Microarray | Early RA detection | Whole blood | Identification of early RA cases is possible due to a massive expression of miRNAs in the early phases of disease | Diagnostic |
| [10]      | LncRNAsMicroarray | RA detection | PBMCs | Identification of the transcriptional patterns of expression associated with disease. Among these LncRNAs ENST00000456270 and NR_002838 are promising | Diagnostic |

RA rheumatoid arthritis, HC healthy controls, OA osteoarthritis, BM biomarkers, FDR first degree relatives, MTX methotrexate, AUC area under curve.

3. The Identification of mRNA, LncRNAs, and miRNAs as Biomarkers in RA

As mentioned earlier, technological advances in biomedicine, functional genomics, and systems biology have resulted in the identification of a growing number of biomarkers with potential use in clinical practice. They can help identify patients with early RA, identify treatment failure, differentiate other diseases, and evaluate disease course. Some of these biomarkers come from omics assays, which evaluate thousands of molecules, working with metadata and summarizing information to provide specific differentially expressed molecules as new biomarkers for RA (Table 2). These still require extensive validation in a real-world clinical setting to demonstrate their efficacy.

**Table 2. Examples of biomarkers in literature with potential clinical use in RA.**

| Biomarker | AUC | P    | % Sensitivity | % Specificity | Reference |
|-----------|-----|------|---------------|---------------|-----------|
| PCNT      | 0.742 | <0.0001 | 71.20%       | 68.60%       | [18]      |
| AFF2      | 0.709 | 0.0007 | 50.90%       | 88.60%       |           |
| SIAE      | 0.713 | 0.0006 | 54.20%       | 82.90%       |           |
| RSAD2     | 0.75  | 0.044 | 75.00%       | 100.00%      |           |
| LY6E      | 0.69  | 0.0581 | 50.00%       | 100.00%      |           |
| IFI6      | 0.71  | 0.0832 | 62.50%       | 100.00%      | [20]      |
|          | 0.82  | 0.005 | 70.00%       | 94.74%       | [4]       |
| WIFI1     | 0.92  | 0.001 | 87.50%       | 92.86%       |           |
| MXA       | 0.81  | 0.005 | 80.00%       | 80.00%       |           |
| SOSTDC1   | 0.93  | <0.001 | 87.50%       | 92.86%       | [4]       |

Values of the biomarkers where obtained when compared to healthy controls. (AUC) Area under the ROC curve.

4. Implications and Perspective of Clinical Applicability in RA

Autoimmune diseases are heterogeneous, and RA is pleomorphic in its clinical presentation, disease course, and response to treatment. In this context, identifying RNA biomarkers among patients in different disease stages provides essential information about pathophysiological pathways, functional genetics, and molecular markers for diagnosis,
prognosis, and therapy individualization. Due to the advent of RNA-based detection of SARS-CoV-2, the necessary infrastructure needed to detect these RNA species by RT-qPCR is now a reality in most places [21,22].

Ethical, social, and legal implications also need to be considered for the broad adoption of these technologies, such as (1) the anonymity of genetic testing results, (2) data privacy, and (3) the adoption of strict policies and rules regarding information gathering, storage, and access by authorized labs and the biotech industry. These aspects have been widely reviewed in detail elsewhere in order to balance clinical testing usefulness and the prediction of future clinically important conditions against the right to privacy of a patient in the ELSI declaration [23,24]. There has been great advancement in this field given that there are institutions in Mexico, such as the National Institute for Access to Information (INAI, in Spanish), responsible for issuing policies, requirements, storage conditions, and access to personal data that companies, or public entities gather from citizens (genetic data included) and access to non-sensitive government information. In the future, these institutional advances will allow for fast, reliable, and state-of-the-art genetic testing with adequate management of the generated data for the benefit of the patient, investigation, and research.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Acknowledgments: We thank Sergio Lozano-Rodríguez from the Universidad Autónoma de Nuevo León for reviewing and editing the English version of the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Koboldt, D.C.; Steinberg, K.M.; Larson, D.E.; Wilson, R.K.; Mardis, E.R. The next-generation sequencing revolution and its impact on genomics. *Cell* 2013, *155*, 27–38. [CrossRef]

2. Gharizadeh, B.; Yue, J.; Yu, M.; Liu, Y.; Zhou, M.; Lu, D.; Zhang, J. Navigating the pandemic response life cycle: Molecular diagnostics and immunoassays in the context of COVID-19 management. *IEEE Rev. Biomed. Eng.* 2020, *14*, 30–47. [CrossRef]

3. Sachinidis, A.; Garyfallos, A. Double Negative (DN) B cells: A connecting bridge between rheumatic diseases and COVID-19? *Mediterr. J. Rheumatol.* 2021, *32*, 192. [CrossRef]

4. Macías-Segura, N.; Castañeda-Delgado, J.E.; Bastian, Y.; Santiago-Algarra, D.; Castillo-Ortiz, J.D.; Aleman-Navarro, A.L.; Jaime-Sánchez, E.; Gomez-Moreno, M.; Saucedo-Toral, C.; Lara-Ramirez, E.E. Transcriptional signature associated with early rheumatoid arthritis and healthy individuals at high risk to develop the disease. *PLoS ONE* 2018, *13*, e0194205. [CrossRef]

5. Wainberg, M.; Sinnott-Armstrong, N.; Mancuso, N.; Barbeira, A.N.; Knowles, D.A.; Golan, D.; Ermel, R.; Ruusalepp, A.; Quertermous, T.; Hao, K. Opportunities and challenges for transcriptome-wide association studies. *Nat. Genet.* 2019, *51*, 592–599. [CrossRef]

6. Plant, D.; Maciejewski, M.; Smith, S.; Nair, N.; Maximising Therapeutic Utility in Rheumatoid Arthritis Consortium, the RAMS Study Group; Hyrich, K.; Ziemek, D.; Barton, A.; Verstappen, S. Profiling of gene expression biomarkers as a classifier of methotrexate nonresponse in patients with rheumatoid arthritis. *Arthritis Rheumatol.* 2019, *71*, 678–684. [CrossRef]

7. Romo-García, M.; Bastian, Y.; Zapata-Zúñiga, M.; Macías-Segura, N.; Castillo-Ortiz, J.; Lara-Ramirez, E.; Fernández-Ruiz, J.; Berlanga-Taylor, A.; González-Amaro, R.; Ramos-Remus, C. Identification of putative miRNA biomarkers in early rheumatoid arthritis by genome-wide microarray profiling: A pilot study. *Gene* 2019, *720*, 144081. [CrossRef]

8. Li, W.C.; Bai, D.L.; Xu, Y.; Chen, H.; Ma, R.; Hou, W.B.; Xu, R.J. Identification of differentially expressed genes in synovial tissue of rheumatoid arthritis and osteoarthritis in patients. *J. Cell. Biochem.* 2019, *120*, 4533–4544. [CrossRef]

9. Ashton, M.P.; Eugster, A.; Dietz, S.; Loebel, D.; Lindner, A.; Kuehn, D.; Taranko, A.E.; Heschel, B.; Gavrisan, A.; Ziegler, A.G. Association of Dendritic Cell Signatures With Autoimmune Inflammation Revealed by Single-Cell Profiling. *Arthritis Rheumatol.* 2019, *71*, 817–828. [CrossRef]

10. Yuan, M.; Wang, S.; Yu, L.; Qu, B.; Xu, L.; Liu, L.; Sun, H.; Li, C.; Shi, Y.; Liu, H. Long noncoding RNA profiling revealed differentially expressed IncRNAs associated with disease activity in PBMCs from patients with rheumatoid arthritis. *PLoS ONE* 2017, *12*, e0186795. [CrossRef]

11. Romo-García, M.F.; Nava-Ramírez, H.S.; Zapata-Zúñiga, M.; Macías-Segura, N.; Santiago-Algarra, D.; Castillo-Ortiz, J.D.; Bastión, Y.; Ramos-Remus, C.; Enciso-Moreno, J.A.; Castañeda-Delgado, J.E. Evaluation of SUMO1 and POU2AF1 in whole blood from rheumatoid arthritis patients and at risk relatives. *Int. J. Immunogenet.* 2019, *46*, 59–66. [CrossRef]
12. Burgers, L.E.; Raza, K.; Van Der Helm-Van, A.H. Window of opportunity in rheumatoid arthritis–definitions and supporting evidence: From old to new perspectives. *RMD Open* 2019, 5, e000870. [CrossRef]

13. Pratt, A.G.; Swan, D.C.; Richardson, S.; Wilson, G.; Hilken, C.M.; Young, D.A.; Isaacs, J.D. A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease. *Ann. Rheum. Dis.* 2012, 71, 1374–1381. [CrossRef]

14. Zhang, R.; Yang, X.; Wang, J.; Han, L.; Yang, A.; Zhang, J.; Zhang, D.; Li, B.; Li, Z.; Xiong, Y. Identification of potential biomarkers for differential diagnosis between rheumatoid arthritis and osteoarthritis via integrative genome-wide gene expression profiling analysis. *Mol. Med. Rep.* 2019, 19, 30–40. [CrossRef]

15. Cheng, Q.; Chen, X.; Wu, H.; Du, Y. Three hematologic/immune system-specific expressed genes are considered as the potential biomarkers for the diagnosis of early rheumatoid arthritis through bioinformatics analysis. *J. Transl. Med.* 2021, 19, 18. [CrossRef]

16. Huang, Y.; Zheng, S.; Wang, R.; Tang, C.; Zhu, J.; Li, J. CCL5 and related genes might be the potential diagnostic biomarkers for the therapeutic strategies of rheumatoid arthritis. *Clin. Rheumatol.* 2019, 38, 2629–2635. [CrossRef]

17. Fernandez-Ruiz, J.C.; Ramos-Remus, C.; Sanchez-Corona, J.; Castillo-Ortiz, J.D.; Castaneda-Sanchez, J.J.; Bastian, Y.; Romo-Garcia, M.F.; Ochoa-Gonzalez, F.; Monsivais-Ureenda, A.E.; Gonzalez-Amaro, R. Analysis of miRNA expression in patients with rheumatoid arthritis during remission and relapse after a 5-year trial of tofacitinib treatment. *Int. Immunopharmacol.* 2018, 63, 35–42. [CrossRef]

18. Luo, Q.; Liu, J.; Fu, B.; Zhang, L.; Guo, Y.; Huang, Z.; Li, J. Circular RNAs Hsa_circ_0002715 and Hsa_circ_0035197 in Peripheral Blood Are Novel Potential Biomarkers for New-Onset Rheumatoid Arthritis. *Dis. Markers* 2019, 2019, 2073139. [CrossRef]

19. Castañeda-Delgado, J.E.; Bastán-Hernandez, Y.; Macias-Segura, N.; Santiago-Algarra, D.; Castillo-Ortiz, J.D.; Alemán-Navarro, A.L.; Martinez-Tejada, P.; Enciso-Moreno, L.; Lira, G.-D.; Olguin-Calderon, D. Type I interferon gene response is increased in early and established rheumatoid arthritis and correlates with autoantibody production. *Front. Immunol.* 2017, 8, 285. [CrossRef]

20. Wright, H.L.; Cox, T.; Moots, R.J.; Edwards, S.W. Neutrophil biomarkers predict response to therapy with tumor necrosis factor inhibitors in rheumatoid arthritis. *J. Leukoc. Biol.* 2017, 101, 785–795. [CrossRef]

21. Da Silva, R.G.L.; Chammas, R.; Novaes, H.M.D. Rethinking approaches of science, technology, and innovation in healthcare during the COVID-19 pandemic: The challenge of translating knowledge infrastructures to public needs. *Health Res. Policy Syst.* 2021, 19, 104. [CrossRef] [PubMed]

22. Dodds, K.; Broto, V.C.; Detterbeck, K.; Jones, M.; Mamadouh, V.; Ramutsindela, M.; Varsanyi, M.; Wachsmuth, D.; Woon, C.Y. The COVID-19 pandemic: Territorial, political and governance dimensions of the crisis. *Territ. Politics Gov.* 2020, 8, 289–298. [CrossRef]

23. Ascencio-Carbajal, T.; Saruwatari-Zavala, G.; Navarro-Garcia, F.; Frixione, E. Genetic/genomic testing: Defining the parameters for ethical, legal and social implications (ELSI). *BMC Med. Ethics* 2021, 22, 156. [CrossRef]

24. Marchant, G.; Barnes, M.; Evans, J.P.; LeRoy, B.; Wolf, S.M. From genetics to genomics: Facing the liability implications in clinical care. *J. Law Med. Ethics* 2020, 48, 11–43. [CrossRef]